Budesonide/Salbutamol

布地奈德/沙丁胺醇

Report date: 2026/05/22 20:01:29

Base Information

Drug NameBudesonide/Salbutamol
Drug Alias NameAIRSUPRAPT-027BDA MDI/PT027
ClassificationSmall molecules > Steroids
Mechanisms of ActionGlucocorticoid receptor agonistsBeta-2 adrenergic receptor agonists
TargetsBeta-2 adrenergic receptorGlucocorticoid receptor
Therapy Area/IndicationsBronchoconstrictionAsthmaRespiratory Tract Diseases
Global Approved IndicationsAsthma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2023/01/10
Country/TerritoryCzechiaCanadaUnited States +[18] 
CombinationsYes BudesonideSalbutamol sulfate
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesPearl Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAvillion LlpAstrazeneca Pharmaceuticals LpAstrazeneca Dunkerque Production +[6] 
Inactive CompaniesN/A
Active IndicationsBronchoconstrictionAsthma
Inactive IndicationsRespiratory Tract Diseases

Other Information

ATC CodeN/A
Related LinksN/A